Ignite Creation Date:
2024-05-06 @ 7:59 PM
Last Modification Date:
2024-10-26 @ 3:18 PM
Study NCT ID:
NCT06217185
Status:
RECRUITING
Last Update Posted:
2024-02-28
First Post:
2023-12-24
Brief Title:
The Efficacy and Safety of Pyrotinib Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2 Advanced Breast Cancer ABC
Sponsor:
Hebei Medical University Fourth Hospital
Organization:
Hebei Medical University Fourth Hospital
Study Overview
Official Title:
The Efficacy and Safety of Pyrotinib Trastuzumab Combined With Taxanes in the Treatment of Early Trastuzumab-treated HER2 Advanced Breast Cancer ABC
Status:
RECRUITING
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a multi-center real-world study in which patients who meet the inclusion criteria will receive treatment with Pyrotinib Trastuzumab Taxanes Taxanes will be used for 6-8 cycles or discontinued due to intolerable Adverse Events AEs after which Capecitabine will be used for rhythmic chemotherapy combined with Pyrotinib Trastuzumab The aim is to explore the efficacy and safety of Pyrotinib Trastuzumab and Taxanes in treating Trastuzumab-treated HER2 Advanced Breast Cancer ABC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None